PR Newswire Europe - Labopharm Initiates Phase III Clinical Study for Once-Daily Formulation of Trazodone.
LAVAL, Canada, June 7 /PRNewswire/ —
- Once-Daily Trazodone Formulation Has Potential to Offer Unique Approach to Treating Major Unipolar Depressive Disorder
Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it has begun enrolling patients in its North American Phase III clinical trial for its once- daily formulation of the antidepressant trazodone (study 04ACL3-001).
Related Results
Hallucinations associated with initiation of guanfacine.(Letters to the Edito…
Labopharm Initiates Phase III Clinical Study for Once-Daily Formulation of Tr…
Impotence and hypnosis
Trazodone
URL Mutual Unveils Unit-of-Use Initiative.(United Research Laboratories and M…
“Depression is one of the most prevalent central nervous system disorders, affecting at least 121 million people globally, and trazodone is widely used in its treatment with more than 14 …
Read the rest of this article with a Free Trial at HighBeam Research.
